Emerging Growth Research Initiates Buy Rating on OSR Holdings with $10 Price Target

Reuters10-20
Emerging Growth Research Initiates Buy Rating on OSR Holdings with $10 Price Target

Emerging Growth Research has initiated coverage on OSR Holdings Inc. $(OSRH)$ with a Buy-Emerging rating and a 12-month price target of $10.00, representing over 1,600% upside from the recent closing price of $0.58. The report highlights OSR Holdings' diversified healthcare portfolio, including subsidiaries focused on immunotherapy, regenerative medicine, and medical device distribution, as well as a pending acquisition of Woori IO, a noninvasive glucose monitoring company backed by Samsung Electronics. The full initiation report is available at https://emerginggrowth.com/wp-content/uploads/2025/10/FINAL-OSRH_Initiation_10.20.25.pdf.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 271104) on October 20, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment